GoodRx Holdings, Inc.·Healthcare
GoodRx Holdings, Inc., through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States. It also offers other healthcare products and services, including subscriptions, pharma manufacturer solutions, and telehealth services. It serves pharmacy benefit managers that manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was incorporated in 2015 and is headquartered in Santa Monica, California.
Healthcare
Medical - Healthcare Information Services
738
2020-09-23
1.55

GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today launched [url="]GoodRx Companion[/url], a new $14.99-per-month subscrip

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today launched GoodRx Companion, a new $14.99-per-month subscription that brings together free and low-cost generic medications, affordable online care visits, and savings on additional healthcare services in one simple program. Built for a healthcare environment where consumers are increasingly shouldering more out-of-pocket costs, even when they have insurance, Companion tu.

You turn 65, sign up for Medicare, and a wall of mail arrives pushing standalone Part D drug plans. The default move for decades has been to pick one and forget it. For 2026, that default deserves a fresh look. The Inflation Reduction Act fully kicks in this year, premiums and surcharges shift, and bundled... 3 Reasons Retirees Should Reconsider Enrolling in a Standalone Medicare Drug Plan in 2026

GoodRx Holdings, Inc. faces ongoing revenue and margin pressure as its legacy business declines and Pharma Direct grows but with lower profitability. GDRX's Q1 results showed a 4% Y/Y revenue drop and EBITDA margin compression to 18.5%, with management expecting continued legacy erosion through 2026. Valuation sensitivity is highest to margin assumptions; the base DCF value is $2.49/share, near the current price, with scenario analysis skewed toward downside risk.

GoodRx Holdings, Inc. (GDRX) Q1 2026 Earnings Call Transcript

Out-of-pocket drug costs are rising for millions of Americans. Coverage gaps are widening.